GOTHENBURG, Sweden –Zinzino’s Group revenue rose 20% in July 2026 compared with the same month last year. Total Group revenue reached SEK 315.9 million, up from SEK 263.8 million.
Revenue from Zinzino’s sales markets increased 20% to SEK 313.4 million, compared with SEK 261.6 million in July 2025. Faun Pharma’s external sales totaled SEK 2.5 million, a 14% rise from SEK 2.2 million.
Accumulated revenue for January to July 2026 grew 22% to SEK 2,174.8 million. This compares with SEK 1,782.0 million in the same period of 2025.
July 2026 vs July 2025 (MSEK)
Region | July 2026 | July 2025 | Change |
The Nordics | 24.5 | 26.1 | -6% |
Central Europe | 98.1 | 76.7 | +28% |
East Europe | 27.4 | 31.6 | -13%* |
South & West Europe | 49.9 | 47.2 | +6% |
The Baltics | 8.7 | 10.0 | -13% |
North America | 64.4 | 47.2 | +36% |
South America | 3.9 | 0.8 | +388% |
Asia-Pacific | 34.3 | 20.1 | +71% |
Africa | 2.2 | 1.9 | +16% |
Zinzino Total | 313.4 | 261.6 | +20% |
Faun Pharma | 2.5 | 2.2 | +14% |
Group Total | 315.9 | 263.8 | +20% |
Year-to-Date 2026 Highlights
Â
Zinzino AB (publ) (ZZ-B.ST) is a global direct-sales company from Scandinavia. It specializes in test-based, personalized nutrition and scientific skincare. The company is listed on Nasdaq First North Premier Growth Market.
There are no reviews yet. Be the first one to write one.